DOAC-BLEED-GFR v1: We present a pre-validation composite scoring framework for ISTH major bleeding at 12 months in adult patients with non-valvular atrial fibrillation or VTE on DOAC therapy with eGFR 15-59 mL/min/1.73m2.
Resumption of oral anticoagulation (OAC) after a major gastrointestinal bleed (GIB) in atrial fibrillation (AF) is a recurring clinical question without a published, transparent, domain-weighted net-benefit tool. Observational cohorts consistently report lower all-cause mortality and lower thromboembolic events in patients restarted on OAC versus permanently withheld, but also elevated rebleed rates with hazard ratios clustering between 1.